

Contents

<i>Preface</i>	v
<i>Contributors</i>	xxiii
1. Non-Viral Gene Therapy	1
<i>Sean M. Sullivan</i>	
1. Introduction	1
2. Plasmid DNA	3
2.1 Plasmid DNA Manufacture	5
3. Plasmid DNA Gene Transfer Methods	6
3.1 Plasmid DNA or “Naked DNA” as a Gene Delivery System	6
3.1.1 Electroporation of Naked DNA	8
3.1.2 Sonoporation of Naked DNA	9
3.2 Plasmid DNA Formulations	9
3.2.1 Cationic Lipids	9
3.2.1.1 <i>In vitro</i> transfection	10
3.2.1.2 Systemic <i>in vivo</i> gene transfer . . .	11
3.2.1.3 Local administration of cationic lipid/pDNA transfection complexes	12
3.3 Polymer	14
3.3.1 Cationic Polymers	14
3.3.2 Neutral Polymer	15
Conclusions	17
References	17

2. Adenoviral Vectors 21

Stuart A. Nicklin and Andrew H. Baker

1. Introduction	21
2. Adenoviral Capsid Structure	22
3. Adenoviral Cell Entry	23
4. Production of Adenoviral Vectors	24
5. Production of Targeted Adenoviral Vectors	26
6. Gene Therapy Applications	28
7. Immune Responses to Ad Vectors	30
8. Safety and Regulatory Issues	32
9. Conclusions	33
References	33

3. Retroviral Vectors and Integration Analysis 37

*Cynthia C. Bartholomae, Romy Kirsten, Hanno Glimm,
Manfred Schmidt and Christof von Kalle*

1. Introduction	37
2. Design, Production and Mechanism of Transduction	38
3. <i>In vivo</i> Application	41
4. Side Effects in Retroviral Gene Therapy	42
4.1 Distribution of Retroviral Integration Sites in the Cellular Genome	42
4.2 Side Effects in Clinical and Preclinical Gene Therapy Studies	45
5. New Strategies for Vector Biosafety in Gene Therapy	47
References	49

4. Lentiviral Vectors 53

*Janka Mátrai, Marinee K. L. Chuah
and Thierry VandenDriessche*

1. Basic Viral Biology	53
2. Vector Design and Production	56
2.1 Vector Development	56
2.2 Vector Production	58

3.	Gene Transfer Concepts and Potential Applications . . .	59
3.1	Target Cells and Diseases	59
3.2	Pseudotyping	59
3.3	Cell Type Specific Targeting	60
3.4	Integration-Defective Lentiviral Vectors	60
4.	Immune Consequences	62
5.	Safety Issues	63
6.	Conclusions and Perspectives	64
	References	64
5.	Herpes Simplex Virus Vectors	69
	<i>William F. Goins, David M. Krisky, James B. Wechuck, Darren Wolfe, Justus B. Cohen and Joseph C. Glorioso</i>	
1.	Introduction	69
2.	HSV Biology in the Design of Replication Defective Vectors	74
3.	HSV Vector Design Technology	77
4.	Gene Transfer/Therapy Applications	79
5.	Immunology	80
6.	Safety and Regulatory Issues	81
7.	Summary	81
	References	82
6.	Adeno-Associated Viral (AAV) Vectors	87
	<i>Nicholas Muzyczka</i>	
1.	Introduction	87
2.	Biology of AAV	88
3.	Vector Technology	93
4.	Vector Characteristics <i>In Vivo</i>	96
5.	Next Generation Vectors	98
6.	Conclusions and Outlook	99
	References	99

7. Regulatory RNA in Gene Therapy 103

Alfred. S. Lewin

1. Introduction	103
2. Delivery of Therapeutic RNAs	106
3. Ribozymes	109
4. RNAi for Gene Therapy	111
5. Gene Therapy Using miRNA	114
6. Aptamers, Decoys and Bi-Functional RNAs	115
7. Modification of Cis-Acting Regulatory RNA Sequences	116
8. Conclusions	119
References	120

8. DNA Integrating Vectors (Transposon, Integrase) 123

Lauren E. Woodard and Michele P. Calos

1. Basic Vector Biology	123
1.1 Transposon Systems	124
1.2 Integrase Systems	126
2. Vector Design and Production	128
2.1 Design of Transposon Systems	128
2.2 Design of Integrase Systems	128
2.3 Production of Plasmid DNA	129
3. Gene Transfer Protocols and Potential Applications	130
3.1 Hepatocyte Transfection via Hydrodynamic Injection	130
3.2 Lipophilic Complexes to Transfect Endothelial Cells and Glioblastoma	131
3.3 Direct DNA Injection and Electroporation to Target Muscle, Retina, and Joints	131
3.4 Integration into Cultured Cells for <i>Ex vivo</i> Gene Therapy	131
4. Immunology	132

5.	Safety and Regulatory Issues	133
5.1	Integration Profiles and Associated Hazards	133
5.2	Efforts to Enhance Integration Specificity	133
5.3	Effects on Tumor Latency in Mouse Models of Cancer	134
	References	135
9.	Homologous Recombination and Targeted Gene Modification for Gene Therapy	139

Matthew Porteus

1.	Introduction	139
2.	Problems with Using Gene Targeting by Homologous Recombination	140
3.	Homologous Recombination in Embryonic Stem Cells	141
4.	Homologous Recombination using Adeno-Associated Virus	144
5.	Site-Specific Modification of the Genome using Double-Strand Breaks	144
6.	Double-Strand Break Repair	144
7.	Double-Strand Break Induced Homologous Recombination	146
8.	Re-design of Homing Endonucleases to Recognize New Target Sites	146
9.	Development of Zinc Finger Nucleases	147
10.	Using Zinc Finger Nucleases to Stimulate Gene Targeting	147
11.	Using Zinc Finger Nucleases to Site-Specifically Modify Genes by Mutagenic Non-Homologous End-Joining	149
12.	Strategies of Zinc Finger Nuclease Design	151
13.	Aspects of Zinc Finger Binding Sites and Structure of Zinc Finger Nucleases	153
14.	Zinc Finger Nuclease Toxicity: Measuring and Minimizing	154

15.	The Challenge of Delivery	156
16.	Future Directions and Promise of Homologous Recombination as a Gene Correction Approach to Gene Therapy	157
	References	157
10.	Gene Switches for Pre-Clinical Studies in Gene Therapy <i>Caroline Le Guiner, Knut Stieger, Alice Toromanoff, Fabienne Rolling, Philippe Moullier and Oumeya Adjali</i>	163
1.	Introduction	163
2.	Rapamycin-Dependent Regulatable System	165
2.1	Molecular Mechanisms Involved in Transgene Regulation	165
2.2	Pharmacology of Rapamycin	166
2.3	Translation Development of the Rapamycin Dependent Regulation System	166
3.	Tetracycline-Dependent Regulatable Systems	168
3.1	Molecular Mechanisms Involved in Transgene Regulation	168
3.2	Pharmacology of Doxycycline (Dox)	171
3.3	Translational Development of Tet-dependant Regulation Systems	171
4.	Other Regulatable Systems	175
5.	General Conclusions	177
	References	177
11.	Gene Therapy for Central Nervous System Disorders <i>Deborah Young and Patricia A. Lawlor</i>	181
1.	Introduction	181
2.	Gene Therapy for Parkinson's Disease	182
3.	Gene Therapy for Temporal Lobe Epilepsy	186
4.	Huntington's Disease Gene Therapy	187
5.	Amyotrophic Lateral Sclerosis (ALS)	189
6.	Gene Therapy for Canavan Disease	190

7.	Gene Therapy for Alzheimer's Disease	191
8.	Conclusions and Outlook	193
	References	194
12.	Gene Therapy of Hemoglobinopathies	197
	<i>Angela E. Rivers and Arun Srivastava</i>	
1.	Introduction	198
2.	β -Thalassemia	198
3.	Sickle Cell Disease	199
4.	Gene Therapy	200
4.1	Oncoretroviral Vector-Mediated Globin Gene Transfer	202
4.2	Lentiviral Vector-Mediated Globin Gene Transfer	203
4.3	Adeno-Associated Viral Vector-Mediated Globin Gene Transfer	204
	References	208
13.	Gene Therapy for Primary Immunodeficiencies	213
	<i>Aisha Sauer, Barbara Cassani and Alessandro Aiuti</i>	
1.	Introduction	214
2.	Adenosine Deaminase (ADA)-deficient SCID	215
3.	X-linked Severe Combined Immunodeficiency (SCID-X1)	218
4.	Gene Therapy for Other SCIDs	220
4.1	V(D)J Recombination Defects	220
4.2	Purine Nucleoside Phosphorylase (PNP) Deficiency	222
4.3	Janus Kinase 3 (Jak3) Deficiency	222
4.4	IL-7R Deficiency	223
4.5	Zeta Associated 70 kDa Phosphoprotein (ZAP-70) Deficiency	223
5.	Wiskott-Aldrich-Syndrome (WAS)	224
6.	Chronic Granulomatous Disease	225
7.	Conclusions and Outlook	227
	References	228

14. Gene Therapy for Hemophilia 233

David Markusic, Babak Moghimi and Roland Herzog

1. Introduction	233
2. Limitations of Hemophilia Treatment With Coagulation Factor Concentrates or Recombinant Coagulation Factors	235
3. Gene Transfer for Correction of Hemophilia	236
3.1 <i>Ex Vivo</i> Gene Transfer of F.VIII and F.IX	236
3.2 <i>In Vivo</i> Gene Transfer of F.VIII and F.IX	237
4. AAV is a Preferred Gene Therapy Vector for <i>In Vivo</i> Gene Transfer to Correct of Hemophilia	238
5. Immunological Considerations for Efficient F.IX Gene Transfer	239
6. Advancements from Small and Large Animal Models of Hemophilia	242
6.1 Murine Hemophilia Models	242
6.2 Canine Hemophilia Models	242
7. Gene Therapy Trials for Hemophilia Past, Present, and Future	244
8. Conclusions	245
References	246

15. Gene Therapy for Obesity and Diabetes 251

Sergei Zolotukhin and Clive H. Wasserfall

1. Introduction	251
2. Understanding Obesity: Why We Get Fat	252
2.1 Genetic Factors: Human Obesity Gene Map	252
2.2 Environmental Factors: The Big Two and Other Causal Contributors	253
3. General Strategies in Gene Therapy for Obesity	253
4. Gene Delivery Vehicles	255
5. Gene Targets for Obesity	255
5.1 Leptin	255
5.2 Neurocytokines	256

5.3	AMP-Activated Protein Kinase (AMPK)	256
5.4	Adiponectin	257
5.5	Wnt-10b	257
5.6	Obesity Gene Menu à la Carte	258
5.7	Obesity and Diabetes	259
	References	260
16.	Gene Therapy for Duchenne Muscular Dystrophy	261
	<i>Takashi Okada and Shin'ichi Takeda</i>	
1.	Introduction	261
1.1	Background of Duchenne Muscular Dystrophy	261
2.	Gene-replacement Strategies using Virus Vectors	262
2.1	Choice of Vector	262
2.2	Modification of the Dystrophin Gene and Promoter	264
2.3	Use of Surrogate Genes	266
3.	AAV-Mediated Transduction of Animal Models	266
3.1	Vector Production	266
3.2	Animal Models for the Gene Transduction Study	267
3.3	Immunological Issues of rAAV	268
3.4	Intravascular Vector Administration by Limb Perfusion	269
3.5	Global Muscle Therapies	269
4.	Safety and Potential Impact of Clinical Trials	270
5.	Development of Alternative Strategies	271
5.1	Design of Read-through Drugs	271
5.2	Modification of mRNA Splicing	272
5.3	<i>Ex Vivo</i> Gene Therapy	272
6.	Future Perspectives	273
6.1	Pharmacological Intervention	273
6.2	Capsid Modification	273
7.	Conclusions and Outlook	273
	References	274

17. Cancer Gene Therapy 279

Kirsten A.K. Weigel-Van Aken

1.	Introduction	280
2.	Targeting the Tumor Cell	280
2.1	DNA Electroporation	280
2.2	Non-Oncolytic Viral Vectors	281
2.2.1	Retrovirus	281
2.2.2	Lentivirus	282
2.3	Oncolytic Viruses	282
2.3.1	Herpesvirus	283
2.3.2	Adenovirus	283
2.3.3	Poxvirus	284
2.3.4	Measles virus	285
2.3.5	Vesicular stomatitis virus	285
3.	Targeting the Immune System	286
3.1	Cancer Vaccines	287
3.1.1	Vaccinia virus	287
3.1.2	Lentivirus	287
3.1.3	Adenovirus	288
3.1.4	Parvoviruses	288
3.2	Mesenchymal Stem Cells (MSC) as Delivery Vehicles	288
3.3	Adoptive T Cell Transfer	288
4.	Targeting the Tumor Microenvironment	289
5.	Challenges and Risks of Cancer Gene Therapy	289
6.	Novel Strategies	290
6.1	Prime/Boost Regimens	290
6.2	Immune Cells as Carriers for Viruses	290
7.	Conclusions	291
	References	291

18. Gene Therapy for Autoimmune Disorders 295

Daniel F. Gaddy, Melanie A. Ruffner and Paul D. Robbins

1.	Introduction	295
2.	Rheumatoid Arthritis	296

2.1	Background	296
2.2	Existing Therapies	296
2.3	Target Tissues and Routes of Delivery	297
2.3.1	Local RA Gene Therapy	297
2.3.2	Systemic RA Gene Therapy	297
2.4	Immunomodulation	298
2.5	Overview of Preclinical Gene Therapy Studies	299
2.6	Overview of Clinical Gene Therapy Studies	301
3.	Type I Diabetes Mellitus	301
3.1	Background	301
3.2	Existing Therapies	302
3.3	Target Tissues and Routes of Delivery	303
3.4	Immunomodulation	303
3.5	Overview of Preclinical Gene Therapy Studies	305
3.6	Overview of Clinical Gene Therapy Studies	306
4.	Conclusions and Outlook	307
	References	308
19.	Gene Therapy for Inherited Metabolic Storage Diseases	311
	<i>Cathryn Mah</i>	
1.	Introduction	311
2.	Lysosomal Storage Diseases	312
3.	Glycogen Storage Diseases	314
4.	Animal Models	315
5.	Cross-Correction Strategies	319
6.	Direct Correction of Target Tissues	321
7.	Conclusions and Outlook	324
	References	324
20.	Retinal Diseases	327
	<i>Shannon E. Boye, Sanford L. Boye and William W. Hauswirth</i>	
1.	Introduction	327
2.	Rod and Cone Photoreceptors	330
3.	Cone Photoreceptors	333
4.	Retinal Ganglion Cells	335

5.	Retinal Pigment Epithelium	337
6.	LCA2 Gene Therapy, a Perspective on Translational Research	339
	References	342
21.	A Brief Guide to Gene Therapy Treatments for Pulmonary Diseases	345
	<i>Ashley T. Martino, Christian Mueller and Terence R. Flotte</i>	
1.	Introduction	345
2.	Common Disorders	346
2.1	Cystic Fibrosis	346
2.2	Alpha-1 Antitrypsin (A1AT)	348
3.	Development of Viral Vectors for Lung Disease	348
3.1	Adenoviral Vectors	349
3.2	Adeno-Associated Viral Vectors	349
3.3	Early Conclusions	349
4.	Enhancing Efficiency	350
4.1	Alternative AAV Viral Vector Serotypes	350
4.1.1	Addition of Expression Enhancing Elements	351
4.2	Adenoviral Vectors	351
4.3	Physiological Hurdles in the Lung Environment	352
5.	Non-Viral Vectors	352
5.1	Cationic Liposomes	352
5.2	Compacted DNA Nanoparticles	353
6.	Gene Therapy Development for Alpha-1 Anti-trypsin	353
7.	Lung Cancer Gene Therapy Development	354
8.	Cystic Fibrosis Animal Models	355
9.	Cell-Based Therapy for Cystic Fibrosis	356
10.	Conclusion and Outlooks	357
	References	358

22. Cardiovascular Disease	361
<i>Darin J. Falk, Cathryn S. Mah and Barry J. Byrne</i>	
1. Introduction	361
2. Therapeutic Targets	362
2.1 Congenital Heart Disease	362
2.2 Coronary Artery Disease and Ischemia/ Reperfusion Injury	365
2.3 Oxidative Stress	365
2.4 Antioxidants	366
2.5 Cardiac Contractility	367
3. Animal Models	367
4. Vector Delivery	368
5. Conclusions and Outlook	374
Acknowledgments	374
References	374
Index	379